Common drug shows promise in reducing obesity, fatty liver, and heart problems

Credit: Unsplash+.

A groundbreaking study from Johns Hopkins Medicine has revealed that a drug initially created for Alzheimer’s and schizophrenia could be a game-changer in treating obesity.

Remarkably, it works without requiring any changes in diet or physical activity.

The Origin of the Drug

The drug, which targets a specific enzyme known as PDE9, was originally developed to treat neurological conditions like Alzheimer’s disease and schizophrenia, as well as sickle cell disease.

Interestingly, this enzyme is also linked to heart diseases caused by high blood pressure.

Researchers at Johns Hopkins discovered that by blocking this enzyme, the drug could potentially tackle several health issues commonly associated with obesity, such as high blood pressure, high blood sugar, high cholesterol, and excessive body fat around the waist.

From Alzheimer’s Treatment to Obesity Solution

Previous Clinical Trials: The drug, identified as PF-04447943, was initially tested in clinical trials for Alzheimer’s disease by Pfizer Inc.

However, it was eventually set aside for this purpose. During the trials, over 100 people took the drug, and it was found to be safe, with no severe side effects.

Current Research: The recent study conducted on mice showed remarkable results. Mice that received this drug experienced significant weight loss without any changes in their diet or exercise routines.

Potential for Human Use: If these findings are consistent in humans, the drug could have extraordinary implications. For instance, an obese person weighing 250 pounds might lose about 50 pounds simply by taking this drug.

This outcome could occur without any modifications to their eating habits or physical activity levels.

Addressing a Widespread Health Issue

Obesity is a major health concern globally, particularly in the United States. According to the Centers for Disease Control and Prevention, more than 40% of American adults are obese. This number increases to 43% among women over the age of 60.

The potential of this drug to combat obesity without the need for diet or lifestyle changes could be a significant breakthrough in medical treatment.

It could provide a much-needed solution for millions of people who struggle with obesity and its associated health risks.


The implications of this research are vast. If the drug’s effectiveness and safety are confirmed in human trials, it could revolutionize the approach to treating obesity and related conditions.

This development is especially crucial considering the high rates of obesity and the myriad of health issues it causes.

By offering a treatment option that doesn’t require drastic lifestyle changes, this drug could improve the quality of life for many and potentially reduce the risk of obesity-related diseases.

The journey from a neurological treatment option to a potential obesity solution is an exciting example of how medical research can take unexpected turns, leading to innovative health solutions.

If you care about liver health, please read studies about a diet that can treat fatty liver disease and obesity, and coffee drinkers may halve their risk of liver cancer.

For more information about liver health, please see recent studies that anti-inflammatory diet could help prevent fatty liver disease, and results showing vitamin D could help prevent non-alcoholic fatty liver disease.

Copyright © 2023 Knowridge Science Report. All rights reserved.